ASCO15: AngioChem Presents ANG1005 Data On Breast Cancer Patients With Brain Metastasis At The 2015 American Society For Clinical Oncology Annual Meeting

Results Demonstrate Clinically Meaningful Tumor Reductions in ANG1005 Treated Breast Cancer Patients with Brain Metastasis as Assessed Using Complementary Approaches

MONTREAL--(BUSINESS WIRE)--Angiochem, a clinical stage biotechnology company creating and developing drugs that cross the blood-brain barrier, today announced that results from an ongoing multi-center Phase II study were presented on Saturday, May 30, 2015 at the 2015 American Society for Clinical Oncology (ASCO) annual meeting being held in Chicago. The trial was designed to evaluate the activity of ANG1005, a novel taxane-peptide conjugate able to cross the blood brain barrier (BBB) and enter cancer cells by targeting the LRP-1 receptor, in metastatic breast cancer patients. These data demonstrate that ANG1005 treated patients experienced tumor reductions of up to 60%.

“These results show that ANG1005 is a promising targeted chemotherapy agent, directed at the metastatic brain lesions in the breast cancer patient population where there are few effective systemic treatment options”

In a poster, titled “ANG1005 for Brain Metastases from Breast Cancer: F-FLT-PET and MRI as Complementary Approaches to Response Assessment,” Angiochem, in collaboration with the National Cancer Institute and the National Health Institute , reported results from an ongoing Phase II study evaluating 32 metastatic brain target lesions in 10 patients receiving 550mg/m2 ANG1005. Intracranial responses in brain metastasis by standard MRI criteria as well as ¹⁸F-FLT (3'-Fluoro-3' deoxythymidine)-PET were evaluated.

• Response assessment by FLT-PET modality was done during cycle 1, and at this evaluation timepoint, 15 of the 32 lesions showed a >20% reduction (pre determined response criterion) post therapy for cycle 1. The FLT-PET uptake reduction exceeded the MRI result in 4 patients.
• Patients then went on to additional cycles of ANG1005 every 21 days, using MRI (CNS RECIST v1.1) response evaluation only. Two of the 10 patients had confirmed partial responses lasting 6 and 18 cycles (ongoing), respectively. Seven patients had stable disease, receiving a median 6 cycles. The best response ranged from -5% to -62% in lesion size, compared to baseline. Three patients remain on study.

“These results show that ANG1005 is a promising targeted chemotherapy agent, directed at the metastatic brain lesions in the breast cancer patient population where there are few effective systemic treatment options,” said Jean-Paul Castaigne, M.D., MBA, President & CEO of Angiochem, “CNS metastases from breast cancer requires not only new CNS-directed therapies designed to cross the BBB, but also improved imaging methodologies to assess drug efficacy.”

About ANG1005

ANG1005 is a novel drug conjugate consisting of 3 molecules of paclitaxel covalently linked to Angiopep-2, designed to cross the blood brain barrier (BBB) via transcytosis after binding to LRP-1. It also gains preferable entry into cancer cells by targeting the LRP-1 and therefore by-passing drug resistance mechanism, such as P-gP.

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB for treating neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of brain malignancies and other CNS indications. Angiochem maintains headquarters in Montreal, Canada.

For additional information about the Company, please visit http://www.angiochem.com.